Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Hence, Sigma-Aldrich's Capex-to-Operating-Income for the
three
months ended in Sep. 2015 was 0.27.
Sigma-Aldrich Capex-to-Operating-Income Historical Data
The historical data trend for Sigma-Aldrich's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sigma-Aldrich's Capex-to-Operating-Income
For the Specialty Chemicals subindustry, Sigma-Aldrich's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sigma-Aldrich's Capex-to-Operating-Income Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, Sigma-Aldrich's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Sigma-Aldrich's Capex-to-Operating-Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Sigma-Aldrich Capex-to-Operating-Income Related Terms
Thank you for viewing the detailed overview of Sigma-Aldrich's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Sigma-Aldrich Corp was incorporated under the laws of the State of Delaware in May 1975. The Company is a life science and a technology company that helps in enhancing human health and safety. The Company manufactures and distributes chemicals, biochemicals and other essential products and equipment products to its customers in research and applied labs as well as in industrial and commercial markets. The Company operates in three units including Research, Applied and SAFC Commercial. The Research unit products and services includes chemicals, reagents and kits, enabling the scientists to discover and develop new drugs and materials; Applied unit products and services includes high quality components and kits, chemical reagents, critical raw materials and certified reference standards, providing customized solutions to and constitute critical components and materials for diagnostic companies, testing laboratories and industrial companies; SAFC Commercial unit's products and services are used by its customers to develop and manufacture pharma, biopharma and electronics products. Its customers include pharmaceutical companies, universities, commercial laboratories, industrial companies, biotechnology companies, non-profit organizations, governmental institutions, diagnostic, chemical and electronics companies and hospitals. The Company's trademarks are the brand names; Sigma-Aldrich, Sigma, Aldrich, Fluka, Riedel-de Haën, Supelco, SAFC, SAFC Biosciences, SAFC Hitech, Genosys, Proligo, Pharmorphix, Cerilliant, Vetec, BioReliance and Cell Marque. The Company is subject to extensive regulation by federal, state and local governments and similar international agencies relating to the manufacture, sale and distribution of its products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:SIQ has been successfully added to your 